A Word from the President

Dear NSGO members,

Time goes so fast that it is difficult to understand that more than eight weeks have passed since we met each other at the 30th Anniversary Meeting of NSGO in Helsinki. The Meeting was a great success with 150 registered participants. I am especially glad that all our past presidents participated in the meeting, not to forget Gerda. It was really a great pleasure to listen to the talks by Kamma and Claes, when they brought the early days of the Society to our attention as if it all had happened not until yesterday. Anniika Riska had chosen an excellent venue for the Meeting, and even negotiated the first warm days of the spring to warm us up. The practical arrangements of the Meeting were again taken care of by Solveig and the rest of the office staff, to the last detail. I thank all speakers for their excellent talks and the Board Members for moderating the sessions. The surgical pre-congress course was a success, and the few members who attended the visit to the Department of Radiotherapy told me that the visit was very well organized.

I take here the opportunity to thank also our Gold Sponsors and Exhibitors for the valuable support they have given to the Meeting and Society. Organizing Annual Meetings without that support would be very difficult, even almost impossible. The Satellite Symposia by SOBI and Lilly fitted well to our main Theme or Sarcomas and other Rare Tumors, and the educational grant AstraZeneca gave to support the NSGO Breakfast Symposium is appreciated.

The feedback participants gave us was in general positive, according to the evaluation forms. However, some felt that there were too many talks on sarcomas. Board will discuss the feedback thoroughly at the Strategic Meeting in September.

I’m writing this column at the O’Hare International Airport while waiting for my flight home. Elisabeth, Line, Mansoor and I participated in the GCIG Meeting as the representatives of NSGO just before ASCO, and trials led by NSGO were represented prominently in both GCIG and ASCO Meetings, thanks to Mansoor.

Welcome to Investigator Meeting on 7-DEC-2017 in Copenhagen and to Annual Meeting 2018 on 19-20-APR-2018 in Lund! Between those Meetings the elections for President-Elect and Board will be organized, which means that the Nominating Committee will start looking for potential candidates already in early autumn.

However, let’s enjoy the summer first!

Johanna Mäenpää, President of NSGO

---

NSGO GOLD SPONSORS 2017
(in alphabetical order)

AstraZeneca
Clovis Oncology
Lilly
Roche
Sobi
Tesarō
Dear NSGO colleagues,

NSGO CTU has considerable accomplishments during 2017. Some of these achievements are listed below.

NSGO Sponsored studies in Ovarian Cancer

ENGOT-OV16 / NOVA
Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

ENGOT-OV24-NSGO / AVANOVA
Niraparib versus niraparib-bevacizumab combination in Women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.

ENGOT-OV30-NSGO / Umbrella
A phase II umbrella trial in patients with relapsed ovarian cancer

NSGO Sponsored studies in Endometrial Cancer

ENGOT-EN1 / FANDANGO
A randomised double-blind placebo-controlled phase II trial of first line combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer.

ENGOT-EN2-DGCC
Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.

ENGOT-EN3 / PALEO
A randomized phase II trial of Palbociclib in combination with letrozole versus letrozole for patients with oestrogen receptor positive recurrent endometrial cancer.

NSGO Sponsored studies in Cervical Cancer

ENGOT-EC-XX / MaRuC
A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy or patients with locally advanced Cervical cancer.

NSGO Publications 2017

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
PMID: 28481967

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer.
PMID:28441255

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
PMID:27993805

Niraparib in Recurrent Ovarian Cancer.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
NSGO Publications 2017 (continued)

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.


NSGO contribution at ASCO 2017

MEET THE PROFESSOR SESSION
Meet the PARP-fessors: Evolution of PARP Inhibitors in the Treatment of Ovarian Cancer

Mansoor Raza Mirza, MD - Speaker

1. Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial. | 2017 ASCO Annual Meeting Abstracts

... chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial. Sub-category: Uterine Cancer Category: Gynecologic Cancer Meeting ...


... placebo in combination with letrozole for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN3/PALEO trial. Sub-category: Uterine Cancer Category: Gynecologic Cancer Meeting ...


... ; Dana-Farber Cancer Institute, Boston, MA; Nordic Society of Gynecologic Oncology (NSGO) and Odense University Hospital, Odense, Denmark; British Columbia Cancer Agency ...

4. PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. | 2017 ASCO Annual Meeting Abstracts

... , Innsbruck, Austria; BGOG, University Hospital Leuven, Leuven, Belgium; NSGO, Copenhagen University Hospital, Copenhagen, Denmark; MANGO, Milan, Italy ...

5. Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. | 2017 ASCO Annual Meeting Abstracts

... Matulonis, For the ENGOT-OV16/NOVA Investigators; Nordic Society of Gynecologic Oncology (NSGO) and Rigshospitalet – Copenhagen University Hospital, Copenhagen, Denmark; Arizona Oncology ...

6. The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC). | 2017 ASCO Annual Meeting Abstracts

... Vall d’Hebrón University Hospital, Barcelona, Spain; Nordic Society of Gynecologic Oncology (NSGO) and Rigshospitalet – Copenhagen University Hospital, Copenhagen, Denmark; Stanford Comprehensive ...
7. Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCCG trial. | 2017 ASCO Annual Meeting Abstracts

... , Eva Roennengart, Frederic Amant; The Finsen Centre, Ballerup, Denmark; NSGO-Karolinska Hospital, Stockholm, Sweden; University of Liege-CHU-ST-NDB, Chenee, ...


... Duesseldorf, Germany; MITO and Istituto Nazionale Dei Tumori, Naples, Italy; NSGO and Odense University Hospital, Odense, Denmark; GINECO and Hôpital Tenon, ...

9. What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients. | 2017 ASCO Annual Meeting Abstracts

... Romania; MITO and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy; NSGO and Tampere University Hospital, Department of Obstetrics and Gynecology, Tampere, Finland ...

10. Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS). | 2017 ASCO Annual Meeting Abstracts

... Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; NSGO and Linköping University and Karolinska Institute, Linköping, Sweden; Stanford Women's Cancer ...

11. The prognostic value of tumor residuals indicated by surgeon, by radiology or an integrated approach by surgeons' assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: An exploratory analysis of the AGO Study led Intergroup trial AGO-OVAR 12. | 2017 ASCO Annual Meeting Abstracts

... , Essen, Germany; AGO and Kliniken Essen Mitte, Essen, Germany; NSGO and Linköping University and Karolinska Institute, Linköping, Sweden; AGO and Coordinating ...

All of the above could not be achieved without your active participation, without tremendous work by the NSGO office staff and without our collaborators.

I wish you all a great summer.

Thank you!

Mansoor Mirza, Medical Director.
Sixteen members of the NSGO joined the surgery group meeting in Helsinki on May the 3rd 2017.

**Topic 1: Staging of cervical cancer**

Jan showed the results from the Nordic survey answered by the Nordic departments in the beginning of 2017. The questionnaires were returned by 19 (86%) centers. The median number of cases treated in each center was 32 (15-120). All, except one center that only used PET-CT, used a combination of imaging for treatment planning. Eighteen (94%) centers used MRI and 15 (79%) centers used PET-CT. The clinicians knew the imaging results before FIGO clinical staging in 14 (74%) centers. The result of the imaging had an influence on the clinical staging in more than half of the centers (11/19 (58%)). Sentinel node was a routine procedure in three (16%) centers and was used in protocol in five (28%) centers. The majority of the Nordic Gynecological Oncology Centers report a FIGO clinical stage influenced by pretreatment imaging. The NSGO surgical group plans to elaborate a proposal for future amendments of the staging guideline and streamlining the reporting of the stage to increase transparency of results. The above mentioned is the headlines from an abstract submitted to the ESGO 2017. Kathrine Fuglsang, Denmark will publish the results in AOGS.

**Topic 2: Nordic registry of sentinel lymph node biopsy in endometrial cancer (NORSEC)**

The first NSGO sentinel node meeting was held in Copenhagen in January this year. At this meeting it was decided that it should be explored whether NFOG has resources and founding possibilities available – this has shown not to be possible. Jan has contacted the EU and there might be some possibilities of running a Nordic database covering 60% of the costs. Jan has planned a meeting with the EU office on May the 23rd. The conclusion at the Helsinki meeting was that it was too early and difficult establishing a Nordic database at the moment. It was decided to wait another two years for evaluating the Nordic database possibilities Jan keeps in contact with EU and attend the planned meeting with EU.

**Topic 3: HIPEC in ovarian cancer**

At the moment Aarhus University Hospital is the only department offering HIPIC in the treatment of advanced ovarian cancer. The Oslo group didn’t get the financial support for HIPEC. No representatives from the Stockholm group at the meeting. In Stockholm an IP protocol is running in advanced ovarian cancer. At the moment Odense University Hospital (OUH) considers the possibilities of performing HIPEC. OUH offers PIPAC as palliative treatment in ovarian cancer.

**Topic 4: Exchange of specialist between departments and countries**

An updated list of exchange-departments is available on the NSGO website (‘about’ - ‘surgery group’ – ‘NSGO exchange between centers’). Some members have used the possibility for exchange in one or two weeks.


Unfortunately, the ENTOG group didn’t want to join this survey. The surgery group decided to conduct the survey in the Nordic countries. A person from each NSGO center will be contacted by Katrine Woie. The names of the contact persons will be emailed to Katrine from the members of the surgery group. Kathrine will be the head of the Nordic survey.

*Minutes by Jan Blaakaer, Aarhus. May 16, 2017*
The NSGO Pathology Group

The Pathology network met on Friday the 5th of May during the NSGO annual meeting and had a range of meetings. Attendance was somewhat small, with Dr. Ben Davidson, Dr. Marit Valla and Dr. Joseph Carlson present. First, we traveled to the Hartman Institutet, where the Department of Pathology is located. There we met Dr. Ralf Butzow, the pathologist in charge of gynecological pathology there (and a prior NSGO Board member).

He gave us a tour of the Department and then we sat down and discussed current issues in the gynecology pathology, and pathology in general, at our local hospitals. We had the chance to meet several Finnish pathologists interested in gynecological pathology. We also had a chance to look at several cases together, some of which were unique and very challenging.

After that meeting we went to the Biomedicum where we had a meeting in the lab of Dr. Anniina Farkkila. Her group is one of several collaborating to study adult granulosa cell tumors, especially their biology, treatment and prognosis. Possibilities for future collaboration were discussed.

Finally, we had a short visit at FIMMIC, a company specializing in digital pathology. They have developed a deep learning algorithm that might be of interest in a research setting for various applications. After these meetings it was time for us to part and head to the airport.

In general the meeting in Helsinki was very interesting, especially the focus on rare tumors, that are often of interest to pathologists. It was especially exciting to learn about the rare gynecologic tumor pathology network in France.

Joseph Carlson, Stockholm.

From left to right: Joseph Carlson, Ben Davidson, Marit Valla and Ralf Butzow.
A Final Word from the Editor

With our annual meeting fresh in mind one cannot but reflect on how we treat our patients with rare tumours and how we can move forward in exploring new (targeted) therapies for these diagnosis. Their rarity also raise the question concerning centralizing the treatment to a few sites within each country to accumulate competence and to guaranty the best available treatment options for our patients. And once again there seems to be an urgent need to find ways to cooperate between our Nordic countries and to bring forward new academic study proposals.

With the excellent scientific program and the highly well-organized 30:th annual meeting in the rear view mirror we have already begun the challenging and ambitious work to make next year’s meeting as interesting and educational as this past meeting.

Well-met in Lund 2018!

Gabriel Lindahl, Linköping

EXHIBITORS AT THE ANNUAL MEETING 2017

AstraZeneca  
Clovis Oncology  
ENDOMED  
KYOWA KIRIN  
LEO  
Lilly  
MSD  
Roche  
Sobi  
TESARO  
Teva Oncology  
Venture
NSGO 30th Annual Meeting in pictures

Speakers

Prof Isabelle Ray-Coquard  
Centre Léon Bérard  
Lyon, France

Prof Ursula Matulonis  
Harvard Medical School  
Boston, USA

Dr Mansoor Mirza  
Rigshospitalet  
Copenhagen, Denmark

Presidents

Claes Tropé  
Norway  
President 1986 - 1991

Kamma Bertelsen  
Denmark  
President 1992 - 1997

Johanna Mäenpää  
Finland  
President 2015 - ongoing

Participants

Snapshots of some of the over 150 participants from the Nordic countries joining together making these meetings worth all the effort!